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Fluvastatin and low-density lipoprotein oxidation in hypercho- lar disease in these patients [1, 2]. Genetic predisposition,
lesterolemic renal transplant patients. immunosuppression with azathioprine, steroids, cyclospo-
Background. Hyperlipidemia contributes to the development rine A (CsA), tacrolimus, and other factors such as obe-and progression of vascular disease in organ transplant patients.
sity, high blood glucose levels, proteinuria, and concomi-Oxidative modification of low-density lipoproteins (LDLs) has
tant treatment with diuretics or b-blockers have beenbeen suggested as a key event in early atherogenesis.
Methods. We conducted a pilot study in renal transplanted related to lipidic abnormalities after renal transplanta-
patients with persistent hypercholesterolemia above 6.5 mmol/ tion [1, 2].
liter. We studied the LDL oxidation before and after one year
On the other hand, oxidative modification of low-den-of fluvastatin treatment. Twenty patients (12 males and 8 fe-
sity lipoproteins (LDLs) has been suggested as being amales, 46 6 10 years old) who received a kidney transplant
24 6 18 months before the study were treated with fluvastatin key event in early atherogenesis [3]. Antioxidant inter-
(20 mg/day for 12 weeks). Patients with a total cholesterol vention can be considered antiatherogenic [4].
under 6.3 mmol/liter continued to receive 20 mg/day for an- In recent years, the inhibitors of 3-hydroxy-methylglu-other 40 weeks (group I, N 5 10). Nine patients with a total
taryl-coenzime A (HMG-CoA) reductase have demon-cholesterol above 6.3 mmol/liter received 40 mg/day for a fur-
strated their ability to reduce cholesterol levels in thesether 40 weeks (group II).
Results. Cyclosporine levels did not experience a significant patients [5]. Fluvastatin is a new synthetic HMG-CoA
variation. Total and LDL cholesterol decreased significantly reductase inhibitor that possesses a distinct pharmaco-
in both groups (21.7 and 27.9% in group I, 18.3 and 27.2% in
logical profile, including a shorter half-life and virtuallygroup II, respectively). The lag-phase time, which was signifi-
no active circulating metabolites [6].cantly enlarged before fluvastatin treatment in the patients
with respect to the controls (N 5 18, 82 6 45 vs. 50 6 8 min) The aim of the study was first to test the efficacy and
was shortened after one year of fluvastatin treatment (64 6 safety of one-year fluvastatin treatment in hypercholes-
24 vs. 50 6 8 min, P 5 0.04). Fluvastatin was stopped in only terolemic cyclosporine A-treated renal transplant pa-one patient because of nausea and vomiting. Transaminases
tients. Second, we analyzed whether fluvastatin possessesand creatin-phospho-kinase were not altered. All of the pa-
an in vivo antioxidant effect on LDL, as has been de-tients maintained a functioning graft during the study period.
Conclusions. Fluvastatin significantly reduced total and LDL scribed in vitro.
cholesterol, without interferences with cyclosporine A through
levels. Fluvastatin has not demonstrated an antioxidant effect
in our renal hypercholesterolemic transplant patients. METHODS
Twenty patients (12 male and 8 female, mean age 46 6
10 years) who received a kidney transplant 24 6 18
Atherosclerosis is a frequent cause of morbidity and
months prior to the treatment with fluvastatin (4 to 59mortality in organ transplant recipients. The different
months) entered the study. All the patients were underfactors involved in the pathogenesis of atherosclerosis
cyclosporine A (CsA) and prednisone immunosuppres-are not completely elucidated, but hyperlipidemia can
sion regimes.contribute to the development and progression of vascu-
The patients had a total cholesterol above 6.5 mmol/
liter in two consecutive observations.
Key words: cyclosporine, hypercholesterolemia, renal transplantation. An American Heart Association (AHA) step I choles-
terol-restriction diet was instituted for three months. The 1999 by the International Society of Nephrology
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patient’s total cholesterol remained higher than 6.5 Statistics
mmol/liter. At this time, we performed basal studies: The Student’s t-test was used to compare means be-
general biochemical parameters in blood and urine and tween groups.
lipidic parameters—total cholesterol, triglycerides, high-
density lipoproteins (HDLs) and subfractions HDL2 and
RESULTSHDL3, very low-density lipoproteins (VLDLs), interme-
diate-density lipoproteins (IDLs) and LDL, and apolipo- After 12 weeks of receiving 20 mg/day of fluvastatin,
10 patients continued receiving 20 mg/day fluvastatinprotein A1, B and C-III. Biochemical parameters and
CsA levels were measured at baseline and after 1, 2, 4, (group I). A further nine patients received 40 mg/day of
fluvastatin because their total cholesterol was main-6, and 12 weeks of treatment and every three months
after that. Total cholesterol and CsA trough levels were tained above 6.3 mmol/liter (group II). In one patient,
fluvastatin was withdrawn three weeks after the initiationmeasured at 13, 14, and 16 weeks in patients from group
II. Lipidic parameters were measured at baseline and because of nausea and vomiting.
The plasma creatinine in group II patients at baselineafter 6 and 12 months of treatment.
The study was divided in two phases: In phase I, the was significantly greater than the plasma creatinine of
group I (Table 1). Proteinuria did not change signifi-patients received fluvastatin (20 mg/day for 12 weeks).
In phase II, patients with a total cholesterol under 6.3 cantly during the study; however, in two patients, pro-
teinuria increased. A kidney biopsy showed a recurrencemmol/liter continued to receive 20 mg/day for another
40 weeks (group I). Those patients with total cholesterol of membranous glomerulonephritis and IgA nephropa-
thy, respectively. Total cholesterol and LDL cholesterolabove 6.3 mmol/liter received fluvastatin 40 mg/day for
a further 40 weeks (group II). In these cases, plasma decreased significantly in both groups. Triglycerides de-
creased in both groups, but not significantly, as well ascreatinine, CsA levels, alanin-amino-peptidase (ALT),
aspartate-amino-peptidase (AST), and creatin-phospho- IDL-cholesterol and apo CIII levels. The pattern of the
kinase (CPK) were carefully monitored at the 13th, 14th, apo CIII distribution in HDL cholesterol and VLDL
and 16th week. cholesterol did not change significantly. Lp(a) levels,
which were higher than normal in group II patients,
Lipidic profile remained at the same values or increased insignificantly
VLDL, IDL, and LDL were separated by preparative in our patients during fluvastatin therapy. Cyclosporine
sequential ultracentrifugation. HDL and HDL3 choles- A trough levels did not significantly change. After the
terol subfraction was obtained by selective immunopre- increase in fluvastatin dose, CsA levels remained stable
cipitation. Cholesterol and triglycerides were deter- (196 6 50 ng/ml in the 12th week and 173 6 36 ng/ml
mined by enzymatic methods. Apolipoprotein A and in the 13th week). Total cholesterol after doubling the
B were measured by immunologic turbidity test. Total dose of fluvastatin was 6.91 6 0.5 mmol/liter at the 13th
apolipoprotein CIII (apo CIII) and apo CIII present in week, 6.14 6 1.9 at the 14th week, and 6.14 6 2.3 at the
the particles without apo B were determined by elec- 16th week.
troimmunodiffusion in agarose gel. Lipoprotein(a) Table 2 shows LDL oxidation susceptibility. All of the
[Lp(a)] was quantitated in serum by enzyme-linked im- patients had a prolonged lag time before treatment with
munosorbent assay. Serum vitamin E and LDL were respect to the control group (P , 0.05). After one year
measured using the Tysen method [7]. of fluvastatin treatment, the lag time was significantly
reduced in group I patients and was reduced but not
Low-density lipoprotein oxidation significantly in group II patients. Compared with control,
Resistance of ultracentrifugated LDL to in vitro oxida- the formation of dienic compounds was lower in trans-
tion was performed as previously described by Hurtado plant patients as was vitamin E levels, but these were
et al [8]. Before oxidation, LDL was dialyzed against not statistically significant. Fluvastatin was well tolerated
degassed phosphate-buffer saline, in a PD 10 (Phar- in all of the patients but one. No significant increases in
macia, Uppsala, Sweden). Oxidation was promoted at ALT, AST, or CPK were observed. All of the patients
378C by the addition of freshly prepared CuSO4. The maintained a functioning graft during the study period.
degree of LDL oxidation was determined by continu- None of our patients developed cardiovascular events
ously monitoring the formation of conjugated dienes during one year of follow-up.
(CD) at 234 nm and several oxidation indexes were calcu-
lated: the initial CD (CDi), maximal CD (CD Max) and
DISCUSSIONthe latency phase (lag phase), that is, the interval of the
In our study, we found that fluvastatin was effectivetime between the intercept of the least-square slope of
and well tolerated, with CsA through levels remainingthe curve with the initial absorbance axis. Lag phase
represents the resistance of LDL to oxidation. stable, as observed by Li et al [9]. Goldberg et al demon-
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Table 1. Evolution of plasma creatinine, proteinuria and lipidic parameters after one year of fluvastatin treatment
Group I (N 5 10) Group II (N 5 9)
Before 6 mo. 12 mo. Before 6 mo. 12 mo.
Creatinine lmol/liter 138644 139 642 141 643 175 641a 176641 167 650
Proteinuria g/day 0.3360.29 0.7 60.8 0.6060.61 0.43 60.5 0.5 60.74 0.4760.6
T. chol. mmol/liter 7.260.5 5.7 60.4 5.6660.7a 8.260.7 6.6 60.7 6.7 60.6a
Triglycerides mmol/liter 2.860.8 1.2 60.3 1.6660.9 3.2 61.8 2.7 61.2 2.7 62.1
HDL-chol. mmol/liter 1.660.4 1.6 60.4 1.5960.4 1.2 60.4 1.2 60.1 1.2 60.3
HDL 2 mmol/liter 0.5860.4 0.49 60.4 0.48 60.4 0.24 60.3 0.39 60.0 0.34 60.34
HDL 3 mmol/liter 1.0460.3 1.11 60.3 1.11 60.4 0.97 60.2 0.9 60.3 0.8660.24
IDL mmol/liter 0.4360.2 — 0.3160.2 0.64 60.27 — 0.57 60.23
LDL mmol/liter 5.160.5 4.0460.7 3.62 60.6a 5.960.6 4.3 60.89 4.3 60.4a
VLDL mmol/liter 0.560.4 0.3 60.1 0.6660.2 0.9 60.4 1.1160.7 1.1 60.6
Apo A1 g/liter 1.860.6 1.7360.3 1.72 60.4 1.6 60.2 1.5860.2 1.44 60.6
Apo B g/liter 1.460.1 1.1160.9 1.13 60.03 1.5 60.1 1.2660.1 1.4 60.3
Apo CIII mg/dl 48.8612.1 — 41.6614.5 63.8 627 — 67 630
Lp(a) mg/dl 20.4622.9 — 23623.1 45 633.9 — 54.4652.8
Abbreviations are: Before, before treatment; HDL, high-density lipoproteins; IDL, intermediate density lipoproteins; LDL, low density lipoproteins; VLDL, very-
low density lipoproteins; Apo A1, A1 apolipoprotein; Apo B, B apolipoprotein; CIII, C3 apolipoprotein; Lp(a), lipoprotein (a).
a P , 0.05
Table 2. Low density lipoprotein (LDL) oxidation susceptibility
Initial DC Final DC
Lag time MR Vitamin E
min lmol/g LDL gLDLmin mg/liter LDL
Group I
before treatment 75623 59612 205626 3.2060.7 1.2560.59
after 12 months 58 624a 56611 193614 3.6860.4 1.1460.34
Group II
before treatment 91666 72630 2576108 3.6660.9 0.8960.29
after 12 months 73 624 60617 192629 3.5660.7 1.1660.9
All the patients
before treatment 82645c 64621 226674 3.4360.8 1.2060.5
after 12 months 64 624b 58614 193622 3.6360.6 1.1460.64
Control group (N 5 18) 5068 6267 223626 5.4060.9 1.3861.09
MR is maximal oxidation rate.
a P 5 0.013, G-I before vs. after
b P 5 0.04, all the patients before vs. after
c P , 0.05, all the patients before treatment vs. the control group
strated that the fluvastatin area under the curve, the Fluvastatin therapy may posses antiatherogenic prop-
maximum plasma concentration, and the time to maxi- erties not only through its hypocholesterolemic effect,
mum plasma concentration were minimally increased but also its inhibitory effect on the susceptibility of LDL
in renal transplant patients, suggesting that fluvastatin to oxidation. Fluvastatin binds to the LDL, preventing
metabolism may be less affected by cyclosporin than the diffusion of free radicals, which are generated under
other reductase inhibitors [10]. oxidative stress, into the lipoprotein core. In our study,
Atherosclerosis may be accelerated by the formation we were not able to demonstrate in vivo the antioxidant
of oxidized LDL by arterial wall cells [11]. Crisol et al effect attributed in vitro to fluvastatin by other authors.
described a decrease in antioxidant defenses associated The lag time was prolonged in the patients with respect
to kidney transplant recipients [12]. It has been demon-
to the controls before treatment and was decreased afterstrated in previous studies that simvastatin, pravastatin,
one year of fluvastatin treatment.cholestyramine, and benzafibrate reduced the ex vivo
Aggressive lipid-lowering therapy might improve notsusceptibility to LDL oxidation among hypercholesterol-
only cardiovascular prognosis but also graft function [1].emic patients [4]. The reduced susceptibility to lipid per-
In this study, the patients with the highest cholesteroloxidation in lovastatin-treated patients is explained by
levels before fluvastatin therapy had poor initial allograftHussein et al because of the fact that hypocholestero-
function. After one year of follow-up, plasma creatininelemic drugs increase cellular LDL receptor synthesis,
did not change significantly in patients from either group,thereby decreasing the susceptibility of LDL to oxida-
tion [13]. and no deleterious effect of doubling fluvastatin dose on
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